United Notions: Corporate and cultural convergence in life sciences M&A 2021
10 June 2021
Mergermarket is pleased to present United notions: Corporate and cultural convergence in life sciences M&A 2021, published in association with Mintz.
It's an exciting time for the life sciences industry and the scene looks set for more strong M&A activity in the near term, with 2021 showing robust activity levels. Dealmaking has continued through an exceptionally disruptive period as COVID-19 has shut down economies, kept employees at home and prevented traveling. And while our survey shows that life sciences businesses have faced challenges in getting deals completed and then managing the process of post-transaction integration, the majority of respondents rate the process as having been successful.
The report reflects the sentiment of 100 senior-level US-based executives at life sciences companies on their most recent experience of M&A in the sector.
Key findings include:
- 60% of respondents believe the Biden administration will be favorable for life sciences dealmaking in the future, including 35% who say it will be very favorable.
- 48% of respondents acquiring or being acquired say that complete integration into the buyer’s business was the strategy chosen for the deal. This is up significantly from last year, when just 25% said this.
- This year, the top rationale for buyers’ most recent M&A transaction is to add to or improve their R&D pipeline for reasons other than patent expirations.